The NHS has wasted £625 million on modern insulin products over the last decade, according to a new report in …
Health secretary Andrew Lansley has urged governments across the world to be “bold and determined” in working together to tackle …

Boehringer Ingelheim has launched its new diabetes drug Trajenta in the UK, with a price tag to match its rival …
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been approved Europe. The European Commission backed Trajenta …

NHS prescribing for diabetes has risen sharply, largely driven by the disease’s growing prevalence in the UK. Spending rose 41% …
New trials for MannKind’s investigational inhaled insulin drug Afrezza have been given the go-ahead by the FDA, potentially breathing new …
Takeda’s Actos is likely to remain on the market in Europe but regulators want the diabetes drug to carry stronger …
A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …

Eli Lilly has highlighted diabetes, oncology, autoimmune diseases and neuroscience as key therapy areas within its growth strategy. Within these …
A third of patients with diabetes admit to regularly missing or not taking insulin treatment three days a month, according …

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been recommended for European approval. It was given …

Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …